Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Cirrhosis

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 48 articles: HTML format

Single Articles

October 2025
1. LEE J, Cha JH, Cho HS, Yang K, et al
   The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study.
   J Gastroenterol. 2025;60:1284-1295.
   PubMed     Abstract available
   
   
   July 2025
2. SUZUKI T, Matsuura K, Tahata Y, Hikita H, et al
   Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy.
   J Gastroenterol. 2025 Jul 1. doi: 10.1007/s00535-025-02282.
   PubMed     Abstract available
   
   
   June 2025
3. KAWAGISHI N, Suda G, Tahata Y, Hikita H, et al
   Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.
   J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02275.
   PubMed     Abstract available
   
   
   May 2025
4. DING H, Lv H, Sui M, Wang X, et al
   Interaction of neuropilin-1 and hepatocyte growth factor/C-Met pathway in liver fibrosis progression in hepatocyte-specific NRP-1 knockout mice.
   J Gastroenterol. 2025 May 26. doi: 10.1007/s00535-025-02262.
   PubMed     Abstract available
   
   
   April 2025
5. HANAMATSU H, Suda G, Ohara M, Ogawa K, et al
   Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
   J Gastroenterol. 2025;60:456-468.
   PubMed     Abstract available
   
   
   March 2025
6. MIWA T, Tsuruoka M, Ueda H, Abe T, et al
   Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.
   J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02232.
   PubMed     Abstract available
   
   
   
7. DU T, Huang Y, Lv Y, Yuan G, et al
   Liver fibrotic burden across the spectrum of hypothyroidism.
   J Gastroenterol. 2025;60:315-327.
   PubMed     Abstract available
   
   
   
8. WANG H, Liu Z, Fan H, Guo C, et al
   Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD.
   J Gastroenterol. 2025;60:306-314.
   PubMed     Abstract available
   
   
   February 2025
9. KOGISO T, Ogasawara Y, Taniai M, Shimada E, et al
   Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease.
   J Gastroenterol. 2025;60:210-221.
   PubMed     Abstract available
   
   
   
10. WATANABE T, Tokumoto Y, Ochi H, Mashiba T, et al
    Clinical factors to predict changes of esophagogastric varices after sustained viral response with direct-acting antiviral therapy.
    J Gastroenterol. 2025;60:222-234.
    PubMed     Abstract available
    
    
    
11. KURODA H, Abe T, Kamiyama N, Oguri T, et al
    Novel subharmonic-aided pressure estimation for identifying high-risk esophagogastric varices.
    J Gastroenterol. 2025;60:187-196.
    PubMed     Abstract available
    
    
    January 2025
12. WEN C, Tao H, Chen H, Pu W, et al
    Single-cell RNA sequencing and functional analysis reveal the role of altered glycosylation levels of hepatic macrophages in liver cirrhosis.
    J Gastroenterol. 2025 Jan 31. doi: 10.1007/s00535-025-02218.
    PubMed     Abstract available
    
    
    December 2024
13. KAMADA Y, Sumida Y, Takahashi H, Fujii H, et al
    Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02179.
    PubMed     Abstract available
    
    
    November 2024
14. IWAMOTO T, Nozaki Y, Inoue T, Suda T, et al
    Histological improvement of fibrosis in patients with hepatitis C who achieved a 5-year sustained virological response to treatment with direct-acting antivirals.
    J Gastroenterol. 2024 Nov 25. doi: 10.1007/s00535-024-02165.
    PubMed     Abstract available
    
    
    October 2024
15. LIU WJ, Wu WJ, Lin CL, Liu CJ, et al
    Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history.
    J Gastroenterol. 2024 Oct 22. doi: 10.1007/s00535-024-02162.
    PubMed     Abstract available
    
    
    
16. SOMA N, Uchida Y, Kouyama JI, Naiki K, et al
    Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis.
    J Gastroenterol. 2024 Oct 16. doi: 10.1007/s00535-024-02160.
    PubMed     Abstract available
    
    
    
17. KAWAGUCHI T, Fujishima Y, Wakasugi D, Io F, et al
    Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
    J Gastroenterol. 2024 Oct 11. doi: 10.1007/s00535-024-02158.
    PubMed     Abstract available
    
    
    
18. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Response to letter to the editor regarding: "Alcohol-associated liver disease increases the risk of muscle reduction and mortality in patients with cirrhosis".
    J Gastroenterol. 2024 Oct 4. doi: 10.1007/s00535-024-02153.
    PubMed    
    
    
    September 2024
19. KUNZLER IL, Da Croce MA, Fornari F
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Sep 23. doi: 10.1007/s00535-024-02154.
    PubMed    
    
    
    
20. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
    Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
    J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
    PubMed     Abstract available
    
    
    
21. KAWAGUCHI T, Murotani K, Kajiyama H, Obara H, et al
    Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials.
    J Gastroenterol. 2024;59:836-848.
    PubMed     Abstract available
    
    
    July 2024
22. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Jul 28. doi: 10.1007/s00535-024-02137.
    PubMed     Abstract available
    
    
    
23. HAO Y, Hao Z, Zeng X, Lin Y, et al
    Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.
    J Gastroenterol. 2024 Jul 19. doi: 10.1007/s00535-024-02134.
    PubMed     Abstract available
    
    
    
24. UOJIMA H, Yamasaki K, Sugiyama M, Kage M, et al
    Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation.
    J Gastroenterol. 2024;59:598-608.
    PubMed     Abstract available
    
    
    
25. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    PubMed     Abstract available
    
    
    June 2024
26. MIWA T, Utakata Y, Hanai T, Aiba M, et al
    Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance.
    J Gastroenterol. 2024 Jun 11. doi: 10.1007/s00535-024-02126.
    PubMed     Abstract available
    
    
    May 2024
27. SUZUKI T, Matsuura K, Nagura Y, Ito K, et al
    MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents.
    J Gastroenterol. 2024 May 13. doi: 10.1007/s00535-024-02115.
    PubMed     Abstract available
    
    
    
28. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
    ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
    PubMed     Abstract available
    
    
    March 2024
29. WANG J, Zhang H, Chen L, Fu K, et al
    CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
    J Gastroenterol. 2024;59:229-249.
    PubMed     Abstract available
    
    
    February 2024
30. NAMISAKI T, Sato S, Yoshiji H
    Role of combined aerobic and resistance exercise in liver cirrhosis.
    J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
    PubMed    
    
    
    January 2024
31. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
    Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
    J Gastroenterol. 2024;59:56-65.
    PubMed     Abstract available
    
    
    December 2023
32. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
    Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
    J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
    PubMed     Abstract available
    
    
    
33. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    PubMed    
    
    
    
34. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    PubMed    
    
    
    
35. UOJIMA H, Nakabayashi K, Yamasaki K, Sugiyama M, et al
    New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease.
    J Gastroenterol. 2023;58:1252-1260.
    PubMed     Abstract available
    
    
    October 2023
36. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    PubMed     Abstract available
    
    
    
37. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    PubMed     Abstract available
    
    
    September 2023
38. WEI M, Chen Y, Wang M, Li J, et al
    Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
    PubMed    
    
    
    
39. JIANG K, Lu S, Li D, Liu M, et al
    Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization.
    J Gastroenterol. 2023;58:894-907.
    PubMed     Abstract available
    
    
    July 2023
40. WEI M, Chen Y, Wang M, Li J, et al
    Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Jul 24. doi: 10.1007/s00535-023-02027.
    PubMed     Abstract available
    
    
    May 2023
41. KIM KA, Choi HY, Ki M, Jang ES, et al
    Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
    J Gastroenterol. 2023 May 17. doi: 10.1007/s00535-023-01999.
    PubMed     Abstract available
    
    
    
42. UENO M, Fujiwara T, Tokumasu H, Mano T, et al
    Real-world efficacy of antibiotic prophylaxis for upper gastrointestinal bleeding in cirrhotic patients in Japan.
    J Gastroenterol. 2023 May 12. doi: 10.1007/s00535-023-02000.
    PubMed     Abstract available
    
    
    
43. YE MP, Lu WL, Rao QF, Li MJ, et al
    Mitochondrial stress induces hepatic stellate cell activation in response to the ATF4/TRIB3 pathway stimulation.
    J Gastroenterol. 2023 May 7. doi: 10.1007/s00535-023-01996.
    PubMed     Abstract available
    
    
    April 2023
44. NAKAI M, Morikawa K, Sasaki T, Kohya R, et al
    Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis.
    J Gastroenterol. 2023 Apr 27. doi: 10.1007/s00535-023-01993.
    PubMed     Abstract available
    
    
    March 2023
45. GAO TM, Zhou J, Xiang XX, Jin SJ, et al
    plenectomy and azygoportal disconnection decreases the risk of hepatocellular carcinoma for cirrhosis patients with portal hypertension bleeding: a 10-year retrospective follow-up study based on the inverse probability of treatment weighting method.
    J Gastroenterol. 2023 Mar 21. doi: 10.1007/s00535-023-01982.
    PubMed     Abstract available
    
    
    
46. CHANG X, Li Y, Sun C, Li X, et al
    High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
    J Gastroenterol. 2023 Mar 16. doi: 10.1007/s00535-023-01970.
    PubMed     Abstract available
    
    
    
47. MA L, Liu Y, Yan Z, Zhang W, et al
    Comparing the predictive ability of portoatrial and portocaval gradient after transjugular intrahepatic portosystemic shunt creation for variceal rebleeding.
    J Gastroenterol. 2023 Mar 9. doi: 10.1007/s00535-023-01977.
    PubMed     Abstract available
    
    
    January 2023
48. ZHANG X, Durham KM, Garza AA, Murali AR, et al
    Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension.
    J Gastroenterol. 2023 Jan 24. doi: 10.1007/s00535-023-01957.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.